Britain is a world-leader in genomics. When I heard George Freeman MP, the chair of the prime minister’s policy board, tell a conference that despite having voted Remain he thought Brexit could lead to a better regulatory framework for genomics, it sounded like a story. Computer Weekly published the resulting article last week.
UK organisations concerned with genomics didn’t seem to want to discuss it, however. Apart from a short statement from the Department of Health and Mr Freeman’s comments, I interviewed a specialist lawyer and Kari Stefansson, the founder of Icelandic genomics firm deCode Genetics, who suggested that public healthcare should only be available if patients participate in genomic research.
Organisations should be considering and talking about the opportunities Brexit brings, as well as working to mitigate its dangers. In public sector IT, some suppliers already serve the UK and other Anglophone countries such as Canada, Australia and New Zealand, given similar legal and political structures; new trade deals could help expand this. And if Brexit allows regulatory changes that boost genomic research, they are surely worth considering.
Brexit is going to happen and is bound to change some things for good, as well as bad. Organisations need to deal with both, regardless of what the people who make them up think about it.
This is from my monthly newsletter, which you can see in full here. Sign up below.